Combination therapy of an inhaled corticosteroid and a bronchodilator is a frontline treatment for asthma and chronic obstructive pulmonary disease (COPD). With the recent approval of roflumilast, phosphodiesterase 4 (PDE4) has received attention as a promising target for the treatment of COPD.  Presented will be the design, synthesis, and biological activity of novel bifunctional compounds derived from a pyrazolopyridyl PDE4 inhibitor and a �2-adrenoceptor agonist, connected by a stable linker.

Dual β<sub>2</sub>-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease: I.  Pyrazolopyridine PDE4 series

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.

Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease: I. Pyrazolopyridine PDE4 series

Dual β₂-adrenoceptor agonists-PDE4 inhibitors for the treatment of respiratory disease: I. Pyrazolopyridine PDE4 series